Source:http://linkedlifedata.com/resource/pubmed/id/15902285
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2005-7-21
|
pubmed:abstractText |
The role of TP53 mutation in transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (t-FL) was examined in a panel of 91 lymph node biopsies derived from 29 patients pre- and post-transformation. The entire TP53 coding sequence was screened and immunocytochemistry performed to determine expression of p53 and its key regulator MDM2. A total of 10 mutations were detected in eight patients (28%), although none were present at FL diagnosis. Mutations were not detected solely at the time of transformation; in three patients, mutated TP53 arose in at least one antecedent FL sample (6 months, 2.5 years and 4 years prior to transformation). Loss of heterozygosity at the TP53 locus occurred in 2/20 informative patients (only in t-FL samples). p53 staining was positive in 82% (9/11) of available biopsies with a missense mutation, and negative in 71% (45/63) with wtTP53. MDM2 expression was significantly higher in t-FL samples (mean 72% positive; 95% confidence interval (95% CI) 68-76%) than FL (mean 58% positive; 95% CI 54-62%) (P<0.001) but did not correlate with TP53 status. TP53 mutation has only a limited role in the transformation of FL, exerting a heterogeneous influence upon phenotypic change. In contrast, dysregulation of MDM2 is frequent and may provide a more rational therapeutic target..
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/MDM2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-mdm2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0887-6924
|
pubmed:author | |
pubmed:copyrightInfo |
Leukemia (2005) 19, 1459-1465.
|
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1459-65
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15902285-Cell Transformation, Neoplastic,
pubmed-meshheading:15902285-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15902285-Humans,
pubmed-meshheading:15902285-Immunohistochemistry,
pubmed-meshheading:15902285-Loss of Heterozygosity,
pubmed-meshheading:15902285-Lymph Nodes,
pubmed-meshheading:15902285-Lymphoma, B-Cell,
pubmed-meshheading:15902285-Lymphoma, Follicular,
pubmed-meshheading:15902285-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:15902285-Mutation,
pubmed-meshheading:15902285-Mutation, Missense,
pubmed-meshheading:15902285-Neoplasm Proteins,
pubmed-meshheading:15902285-Nuclear Proteins,
pubmed-meshheading:15902285-Proto-Oncogene Proteins,
pubmed-meshheading:15902285-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:15902285-Tumor Suppressor Protein p53
|
pubmed:year |
2005
|
pubmed:articleTitle |
A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
|
pubmed:affiliation |
Cancer Research UK Medical Oncology Unit, Bart's and The Royal London School of Medicine and Dentistry, London, UK. Andrew.J.Davies@cancer.org.uk
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|